10316-79-7

Usage

Uses

Used in Medicinal Chemistry Synthesis:
CYCLOLEUCINOL is used as a building block in medicinal chemistry synthesis for its ability to be easily modified and incorporated into complex molecular structures. Its presence in a molecule can contribute to the overall pharmacological properties, such as potency, selectivity, and bioavailability, of the final drug product.
Used in the Synthesis of Xanthine-Derived Hetrocyclic Fused Systems:
CYCLOLEUCINOL has been specifically used in the synthesis of xanthine-derived heterocyclic fused systems. Xanthine derivatives are known for their diverse range of biological activities, including bronchodilatory, diuretic, and stimulant effects. The incorporation of CYCLOLEUCINOL into these systems can potentially enhance their therapeutic properties or introduce new pharmacological actions.

InChI:InChI=1/C6H13NO/c7-6(5-8)3-1-2-4-6/h8H,1-5,7H2/p+1

Upstream product

• 52-52-8 1-amino-1-cyclopentanecarboxylic acid 
• 78388-61-1 cycloleucine methyl ester 
• 49830-37-7 1-amino-1-cyanocyclopentane 
• 120-92-3 cyclopentanone 
• 60421-23-0 cycloleucine methyl ester hydrochloride 
• 76910-12-8 1-Chlorformyl-1-cyclopentancarbonsaeure-ethylester 
• 54378-87-9 1,1-cyclopentanedicarboxylic acid monoethyl ester 
• 4167-77-5 cyclopentane-1,1-dicarboxylic acid diethyl ester 
• 185-60-4 1-oxaspiro[2.4]heptane 
• 404344-97-4 1-azido-1-hydroxymethylcyclopentane 
• 1664-35-3 ethyl 1-aminocyclopentanecarboxylate 

Downstream Products

• 140396-16-3 7-Benzyl-2-(1-hydroxymethyl-cyclopentylamino)-1-methyl-1,7-dihydro-purin-6-one 
• 1027187-33-2 7-Benzyl-2-(1-hydroxymethyl-cyclopentylamino)-1-methyl-8-phenyl-1,7-dihydro-purin-6-one 
• 1027185-05-2 7-Benzyl-8-cyclopentylmethyl-2-(1-hydroxymethyl-cyclopentylamino)-1-methyl-1,7-dihydro-purin-6-one 
• 251562-04-6 C₁₉H₁₉NO₄ 
• 766550-18-9 1-benzyl-4-(1-hydroxymethylcyclopentyl)piperazine 
• 676560-72-8 N-benzyloxycarbonyl-1-(hydroxymethyl)-1-cyclopentylamine 
• 917893-90-4 (4S,5R)-5-[2-(Diphenyl-phosphinoyl)-phenyl]-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid (1-hydroxymethyl-cyclopentyl)-amide 
• 134656-18-1 14-aza-7-oxadispiro[4.2.5.1]tetradecane 
• 363192-23-8 C₂₃H₄₂N₂O₃ 
• 1496147-51-3 C₁₂H₁₆N₂O₅S 
• 247567-04-0 2-[1-(Hydroxymethyl)cyclopentylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 1021869-77-1 C₂₈H₄₂N₂O₃Si 
• 1124216-18-7 1-(4-(1-(3-((1-(hydroxymethyl)cyclopentyl)carbamoyl)benzyl)piperazine-4-carbonyl)phenyl)-3-phenylurea 2,2,2-trifluoroacetate 

Relevant academic research and scientific papers

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY

This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE

Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS

Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein.

Sterically demanding, bioxazoline-derived N-heterocyclic carbene ligands with restricted flexibility for catalysis

A unique family of N-heterocyclic carbenes derived from bioxazolines (IBiox) suitable for application in transition-metal catalysis is described. The ligands are electron rich, sterically demanding, and have restricted flexibility. Their usefulness has been demonstrated in the Suzuki-Miyaura cross-coupling of sterically hindered aryl chlorides and boronic acids. For the first time, tetraortho-substituted biaryls with methyl and larger ortho-substituents have been synthesized from aryl chlorides using the Suzuki-Miyaura method.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Enantioselective route to key intermediates in the synthesis of carbocyclic phosphoribosyltransferase transition state analogues

The enantioselective preparation of key intermediates in the synthesis of transition state analogues of hypoxanthine-guanine phosphoribosyltransferase, (1S,2S,3R,4R)-4-acetoxymethyl-1-bromomethyl-2,3-isopropylidenedioxy-1- toluenesulfonamidocyclopentane (3a) and the 4-nitrobenzenesulfonamido analogue (3b), are described.

Cyclit-Reaktionen, II. Darstellung von Bausteinen zur Synthese carbocyclischer Furanose-Analoga

The four isomeric hydroxycyclopentenmethanols 6a to 9a can easily be made by allylhydroxylation of the epoxides 2 and 4 with phenyl selenide.In a second way the pair 8a and 9a has been synthesized from 11 via 15.As the preparation of 20 demonstrates, the functionalisation of 6a to 9a to carbocyclic furanoses is possible.The dicarboxylic diethyl esters 23 and 33 can be converted into models for carbocyclic ketofuranoses.